Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

and simultaneously determined that Tyvaso DPI® qualifies for a three-year New Clinical Investigation (NCI) exclusivity for the chronic use of dry powder formulations of treprostinil for the ...

The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...

United Therapeutics will sponsor the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Sympo SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 10, 2024--United Therapeutics ...

You can now play an even larger range of puzzles on our site, every weekday and now also every Saturday. Check out our brand new puzzles below, from Hangman to Add Up and even a Jigsaw. Of course ...

After hours: March 21 at 7:15:55 PM EDT Loading Chart for MNKD ...

After hours: March 20 at 4:46:28 p.m. EDT Loading Chart for UTHR ...